Vericel CORP Form 4 insider transactions

Vericel Corp's Chief Operating Officer, Michael Halpin, exercised stock options and subsequently sold a portion of his common stock holdings.

Vericel Corp Director Kevin F. McLaughlin exercised stock options and subsequently sold 7,000 shares of common stock for $38.59 per share under a pre-arranged trading plan.

Vericel Corp's Chief Operating Officer, Michael Halpin, exercised stock options and subsequently sold an equal number of shares under a pre-arranged trading plan.

Vericel Corp's Principal Accounting Officer, Jonathan Siegal, reported the vesting of Restricted Stock Units and subsequent tax-related share disposals.

Vericel Corp's Chief Medical Officer, Jonathan Hopper, exercised stock options and subsequently sold 10,000 shares of common stock on September 2, 2025, under a pre-arranged 10b5-1 plan.

Vericel Director Kevin McLaughlin exercised stock options and subsequently sold an equal number of shares for a significant gain, as part of a pre-arranged trading plan.

Vericel Corp's Chief Medical Officer, Jonathan Mark Hopper, reported the exercise of stock options and subsequent sale of 10,000 common shares, executed under a Rule 10b5-1 trading plan.

Dominick Colangelo, President and CEO of Vericel Corp, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Kevin McLaughlin, a director at Vericel Corp, exercised stock options and sold 7,000 shares of common stock at $39.98 per share on May 7, 2025, according to a pre-arranged Rule 10b5-1 trading plan.

Director Heidi Hagen reports acquisition and disposal of Vericel Corp common stock and derivative securities related to vesting of Restricted Stock Units and stock options.

Director Lisa Wright reports acquisition and disposal of Vericel Corp stock and derivative securities related to restricted stock units and stock options.

Director Kevin McLaughlin reports acquisition of Vericel Corp stock through vesting of restricted stock units and grant of stock options.

Director Robert Zerbe reports acquisition and disposal of Vericel Corp stock and derivative securities due to RSU vesting and option grants.

Director Paul Wotton reports acquisition and disposal of Vericel Corp common stock and derivative securities due to vesting of restricted stock units and stock option grants.

Director Alan Rubino reports acquisition of Vericel Corp common stock through vesting of restricted stock units and grant of stock options.

Karen Mahoney, Chief Human Resources Officer of Vericel Corp, reports the acquisition of 5,175 Restricted Stock Units (RSUs) on April 30, 2025, vesting annually from February 20, 2026.

Dominick Colangelo, President and CEO of Vericel Corp, exercised stock options and sold shares of common stock on April 9 and 10, 2025, according to a pre-arranged Rule 10b5-1 trading plan.

Vericel Corp's CEO, Dominick Colangelo, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Michael Halpin, Chief Operating Officer of Vericel Corp, exercised stock options and sold 10,000 shares of common stock at $49.52 each on March 3, 2025, according to a Form 4 filing.

Director Heidi Hagen exercised stock options and sold shares of Vericel Corp common stock under a pre-arranged Rule 10b5-1 trading plan.

Vericel Corp's Chief Financial Officer, Joseph Mara, sold 9,000 shares of common stock on March 3, 2025, at a price of $49.53 per share, according to a Form 4 filing with the SEC.

Chief Medical Officer Jonathan Hopper reports exercising stock options and selling shares of Vericel Corp under a pre-arranged trading plan.

Chief Medical Officer Jonathan Hopper reports acquisition and disposal of Vericel Corp stock and restricted stock units (RSUs) related to vesting and tax obligations.

Dominick Colangelo, President and CEO of Vericel Corp, reports the acquisition and disposal of company stock following the vesting of restricted stock units.

Chief Operating Officer Michael Halpin reports acquisition and disposal of Vericel Corp stock related to vesting of restricted stock units and tax withholding.

Chief Financial Officer Joseph Mara of Vericel Corp reports the vesting of restricted stock units and subsequent stock transactions.

Chief Legal Officer Sean Flynn reports acquisition and disposal of Vericel Corp stock, including vesting of Restricted Stock Units and sales under a 10b5-1 trading plan.

Principal Accounting Officer Jonathan Siegal of Vericel Corp reports acquisition and disposal of common stock and restricted stock units.

Jonathan Siegal, Principal Accounting Officer of Vericel Corp, reports the acquisition of stock options and restricted stock units.

Karen Mahoney, Chief Human Resources Officer of Vericel Corp, reports the acquisition of stock options.